Literature DB >> 34924380

Effect of Long-Term Storage on the Reliability of Blood Biomarkers for Alzheimer's Disease and Neurodegeneration.

Carla R Schubert1, Adam J Paulsen1, A Alex Pinto1, Natascha Merten2, Karen J Cruickshanks1,2.   

Abstract

BACKGROUND: Stored blood samples from longitudinal cohort studies may be useful for studying biomarkers of preclinical Alzheimer's disease.
OBJECTIVE: This study aimed to determine the reliability of amyloid-β40 and amyloid-β42 (Aβ40, Aβ42), total tau (TTau), and neurofilament light (NfL) concentrations measured in blood samples stored long-term at -80°C.
METHODS: Aβ40, Aβ42, TTau, and NfL were measured in serum and plasma samples from two longitudinal cohort studies. Serum samples had been stored at -80°C for 5 (n = 24), 14 (n = 24), and 20 years (N = 78) and plasma samples had been stored for 16 years (N = 78). Biomarker concentrations were measured in duplicate using a single molecule array assay (Simoa; Quanterix, Billerica, MA). Replicate samples for each sample type and storage length were included.
RESULTS: The concentrations of Aβ40, Aβ42, TTau, and NfL were within expected ranges. Some serum TTau concentrations were below the limit of detection. The average intra-assay coefficients of variation (CV) for duplicate measures were 2-7% for all assays except for serum TTau, which were higher (CVs 13% and 17%). Mean differences in original replicate pair Aβ40, Aβ42, and NfL concentrations were slightly greater in samples stored for longer versus shorter time periods.
CONCLUSION: Aβ40, Aβ42, TTau, and NfL can be measured in serum and plasma samples that have been stored up to 20 years at -80°C. Long-term storage may be associated with small increases in the variability of concentrations in samples stored 14 or more years.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-β; blood biomarkers; epidemiology; neurofilament light; plasma; serum; single molecule array; total tau

Mesh:

Substances:

Year:  2022        PMID: 34924380      PMCID: PMC8821323          DOI: 10.3233/JAD-215096

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  21 in total

1.  Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.

Authors:  Jeffrey L Dage; Alexandra M V Wennberg; David C Airey; Clinton E Hagen; David S Knopman; Mary M Machulda; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2016-07-18       Impact factor: 21.566

2.  Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.

Authors:  Matthew P Pase; Alexa S Beiser; Jayandra J Himali; Claudia L Satizabal; Hugo J Aparicio; Charles DeCarli; Geneviève Chêne; Carole Dufouil; Sudha Seshadri
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

3.  The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study.

Authors:  Scott D Nash; Karen J Cruickshanks; Ronald Klein; Barbara E K Klein; F Javier Nieto; Guan H Huang; James S Pankow; Theodore S Tweed
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-02-21

4.  Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma.

Authors:  Grant C O'Connell; Megan L Alder; Allison R Webel; Shirley M Moore
Journal:  Bioanalysis       Date:  2019-11       Impact factor: 2.681

5.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Authors:  Jens Kuhle; Christian Barro; Ulf Andreasson; Tobias Derfuss; Raija Lindberg; Åsa Sandelius; Victor Liman; Niklas Norgren; Kaj Blennow; Henrik Zetterberg
Journal:  Clin Chem Lab Med       Date:  2016-10-01       Impact factor: 3.694

6.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  Plasma β-amyloid in Alzheimer's disease and vascular disease.

Authors:  Shorena Janelidze; Erik Stomrud; Sebastian Palmqvist; Henrik Zetterberg; Danielle van Westen; Andreas Jeromin; Linan Song; David Hanlon; Cristina A Tan Hehir; David Baker; Kaj Blennow; Oskar Hansson
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

8.  Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.

Authors:  Piotr Lewczuk; Natalia Ermann; Ulf Andreasson; Christian Schultheis; Jana Podhorna; Philipp Spitzer; Juan Manuel Maler; Johannes Kornhuber; Kaj Blennow; Henrik Zetterberg
Journal:  Alzheimers Res Ther       Date:  2018-07-28       Impact factor: 6.982

9.  Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles.

Authors:  Ashvini Keshavan; Amanda Heslegrave; Henrik Zetterberg; Jonathan M Schott
Journal:  Alzheimers Dement (Amst)       Date:  2018-07-02

10.  Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.

Authors:  Nicholas J Ashton; Antoine Leuzy; Yau Mun Lim; Claire Troakes; Tibor Hortobágyi; Kina Höglund; Dag Aarsland; Simon Lovestone; Michael Schöll; Kaj Blennow; Henrik Zetterberg; Abdul Hye
Journal:  Acta Neuropathol Commun       Date:  2019-01-09       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.